CYCNHealthcare · BiotechnologyCYCN Stock Forecast: Cyclerion Therapeutics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
CYCN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Cyclerion Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Volatility (15): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Cyclerion Therapeutics, Inc. — and when they’d sell — is the membership.
CYCN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CYCN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2021 | Truist Securities | Initiates | Buy | $14 |
| 24 Sept 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CYCN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Cyclerion Therapeutics, Inc. (CYCN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −3.1×
- Price / sales
- 7.5×
- Price / book
- 2.1×
- EV / EBITDA
- −1.9×
Cheaper than 87% of US stocks
Cheaper than 17% of US stocks
Cheaper than 44% of US stocks
Cheaper than 71% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −337.4%
- Net margin
- −264.7%
Higher than 1% of US stocks
Higher than 9% of US stocks
Higher than 1% of US stocks
- Return on equity
- −67.8%
- Return on assets
- −45.8%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CYCN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CYCN appears on the weeks it earns a place.
Frequently asked questions about CYCN stock
How does Ticker Nerd's model rank CYCN?
As at 1 Aug 2026, Cyclerion Therapeutics, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
What is the CYCN stock forecast for 2030?
No analyst covering Cyclerion Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYCN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $8 over the next 12 months.
How has CYCN stock performed over the past year?
Cyclerion Therapeutics, Inc. returned +34.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cyclerion Therapeutics, Inc. do?
Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on discovering, developing, and commercializing innovative human therapeutics.
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on discovering, developing, and commercializing innovative human therapeutics. The company specializes in soluble guanylate cyclase stimulators, small molecules that work synergistically with nitric oxide to enhance cyclic guanosine monophosphate production. Cyclerion's lead program combines validated therapeutic modes of action with a personalized, tech-enabled delivery system targeting neuropsychiatric diseases. The company's foundational product candidate is CYC-126, an individualized therapy designed for treatment-resistant depression, a condition with significant unmet medical need. Cyclerion leverages well-characterized pharmacological approaches paired with biofeedback-driven technology to address complex neurological conditions and advance precision medicine in mental health treatment.
CEO Dr. Regina M. Graul Ph.D. · 1 employees · United States · https://www.cyclerion.com